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Editor-in-Chief
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    January 21, 2020
Dear Professor Racke
After receiving comments from reviewers, I am submitting to you a 
revised version of the manuscript entitled “Aspects of the Immune 
System that Impact Brain Function”. 
The changes that have been made in response to these reviews are 
listed on the appropriate attachment.  I hope that some of the 
suggestions have resulted in a strengthened manuscript.
I would be grateful for your consideration of this revised version for 
publication in the Journal of Neuroimmunology.  
Sincerely,
Stephen Bondy, Ph. D.
Professor
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Reviewer 1
1] The following section is well written: 3.3.2. Slowing onset genetic changes characterizing 
aging. The author argues in favor of the “use of inexpensive agents such as melatonin, which has 
been shown to reverse many of the age-related changes modification of the gene expression 
profile”. Here it is important to mention the work showing melatonin level is itself decreasing 
with age.   Refs:
Age-related changes in serum melatonin in mice: higher levels of combined melatonin and 6-
hydroxymelatonin sulfate in the cerebral cortex. J Pineal Res. 36(4):217-23. The MT2 melatonin 
receptor subtype is present in human retina and decreases in AD, Curr Alzheimer Res. 4(1):47-
51. Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the 
murine cerebral cortex. J Pineal Res. 36(4):224-31.
Response Two references suggested (Lahiri et al., 2004a,b) are now added and discussed in text
2] Section: 2.2.4 Environmental factors: This is an important are. The author should provide a 
"big picture" of the human disease, particularly as complex  as AD. Refs: Epigenetics of 
dementia: understanding the disease as a transformation rather than a state.  Lancet Neurol. 
15(7):760-74; Mol. Psychiatry 14(11):992-1003; Curr Alzheimer Res. 9(5):563-73.  --Role of 
environmental contaminants in the etiology of AD. Curr Alzheimer Res.12(2):116-46. 
Response  The reference suggested, (Yegambaran et al.,2015) is added. In addition, a reference 
to the role of abnormal epigenetic profiles in neurodegenerative events, is included (Lardenoije 
et al., 2015).
3] Re the topic of Immunotherapy, Bondy may consider on touching these points. An 
inflammation-related nutrient pattern is associated with both brain and cognitive measures in a 
multiethnic elderly population’. Yu G et al.  CAR. 5(5): 493–501. - IVIG treatment exerts 
antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease. Counts et 
al.  J Clin Immunol. 2014;34 Suppl 1:S80-5.
Response  A new subsection containing 4 additional references has been added (3.3.4) on 
immunotherapy.  A suggested, the reference on diet and inflammation (Gu et al., 2018), is added 
to the section on diet 3.3.3.
 
Reviewer 2
Please include astroglia in the key words
Response  This has been done
2.1.1. Intensity can allow is repeated in the last line.
Response This error is corrected.
Regarding the meningeal lymphatic system, it is necessary to include a reference supporting this 
important point.
Response   An appropriate reference is added (De Mesquita et al., 2018).
3.1 It is not so clear than microglia are derived from systemic monocytes despite single cell RNA 
sequence studies (Goldman et al.,2016; Ginhoux and Garel 2018); please, moderate the sentence. 
In the same line the last sentence, “the proportion of cerebral microglia (microglia is always 
cerebral) of systemic origin is elevated in some neurodegenerative pathologies…” is not 
unequivocally demonstrated.
Response.  The sentence “However, single-cell RNA sequencing has found that some of these 
are derived from systemic monocytes”   has been altered to “However, single-cell RNA 
sequencing has provided results suggesting that some of these are derived from systemic 
monocytes”.  This is now more suggestive than definitive. 
3.2.3. Astroglia
That astrocytes can clear cell dead and “kill microorganisms” needs a reference. That astrocytes 
can act as real APCs have been a hot debate matter for a long time.
Response   A reference describing astroglial autophagy is added (Lui et al., 2018),  and the 
reference to Shechter and Schwartz (2013), is removed.  The issue of whether astroglia can kill 
micro-organisms has been removed,  as it is a large area in itself.  A reference is also added 
concerning the likelihood of astroglia acting as viral reservoirs and thus enhancing viral survival 
in the brain (Li et al., 2016).
Highlights
 Effective immune responses involve well targeted specificity, appropriate 
duration, and  relevant strength.
 Many slow, progressive disease states are consequent to failure of one or more 
of these critical factors. 
 The most common immune failure is excess inflammation either irrelevant, or 
extended beyond its useful phase.  The prevalence of this apparent shortcoming 
may relate to the increased the longevity of modern times.
 The nervous system has a distinctive vulnerability to excess inflammatory 
activity, both intrinsic and of systemic origin, which progresses with age.
The conditions required for effective immune responses to viral or bacterial organisms and 
chemicals of exogenous origin and to intrinsic molecules of abnormal configuration, is briefly 
outlined.  This is followed by a discussion of endocrine and environmental factors that can lead 
to excessive continuation of immune activity and persistent elevation of inflammatory 
responses. The role of aging events in facilitating such disproportionate activity, is considered.  
The specific vulnerability of the nervous system to prolonging immune events is emphasized.  
In addition of being a target for inflammation associated with neurodegenerative disease, the 
nervous system is also seriously impacted by systemically widespread immune disturbances.  
The means by which immune information can access the CNS and the varying types of 
activation of those cells that regulate immune responses within the brain are discussed.  Some 
possible reasons underlying the relatively common occurrence of derangement and 
hyperreactivity of the  complex immune system are considered, and a few potential ways of 
addressing this common problem receive mention.  
Aspects of the Immune System  that Impact Brain Function
Stephen C. Bondy 
Center for Occupational and Environmental Health, Department of Medicine, University of 
California, Irvine, California 92617, USA
Correspondence to:
Stephen C. Bondy, Ph. D.
Center for Occupational & Environmental Health
Department of Medicine
University of California, Irvine
100 Theory, Suite 100
Irvine, CA 92617-1830
USA
Tel: 1-949-824-8077
scbondy@uci.edu
Aspects of the Immune System  that Significantly Impact Brain Function
1. Background
2.  General Attributes of Immune Mechanisms
2.1. Decisive Features of Immune Responses
2.1.1 Intensity
2.1.2 Specificity
2.1.3 Persistence
2.2.  Inappropriate continued activity of the immune system
2.2.1  Insulin
2.2.2  Glucocorticoids
2.2.3 Aging
2.2.4 Environmental Factors
3.  The Immune System and the Brain
3.1. Susceptibility of the Nervous System to Prolonged Immune Activity
3.2.  Role of macrophages,  microglia and astroglia
3.2.1  Polarity of activated immune cells
3.2.2  Microglial ablation studies
3.2.3  Astroglia
3.2.4  Micro-RNAs
3.3.  Potential therapeutic directions
3.3.1  Mitochondrial protection
3.3.2  Slowing onset genetic changes characterizing aging
3.3.3  Reduction of glycemic potency of diet
3.3.4  A role for immunotherapy
4. Conclusion
Abstract
The conditions required for effective immune responses to viral or bacterial organisms and 
chemicals of exogenous origin and to intrinsic molecules of abnormal configuration, are briefly 
outlined.  This is followed by a discussion of endocrine and environmental factors that can lead 
to excessive continuation of immune activity and persistent elevation of inflammatory 
responses.  Such disproportionate activity becomes increasingly pronounced with aging and 
some possible reasons for this are considered.  The specific vulnerability of the nervous system 
to prolonged immune events is involved in several disorders frequently found in the aging 
brain.  In addition of being a target for inflammation associated with neurodegenerative 
disease, the nervous system is also seriously impacted by systemically widespread immune 
disturbances since there are several means by which immune information can access the CNS.  
The activation of glial cells and cells of non-nervous origin that form the basis of immune 
responses within the brain, can occur in differing modes resulting in widely differing 
consequences.  The events underlying the relatively frequent occurrence of derangement and 
hyperreactivity of the  immune system are considered, and a few potential ways of addressing 
this common condition are described.  
Keywords:  Neurodegeneration: Neuroinflammation, Immune, Microglia, Astroglia, 
Macrophage, Aging
1. Background
The immune system is a complex and sophisticated means of detecting aberrant 
macromolecules and promoting their dissolution or removal.  This precision allows an effective 
shield against invasive pathogenic organisms and also enables removal of endogenous cells that 
are damaged or abnormal.  The homeothermic nature of mammals ensures that protein 
structures are maintained in a relatively consistent configuration, in contrast to cold-blood 
phyla where these configurations can flux considerably with changing external temperature.  
This constancy allows the immune system to be especially selective and sensitive.  As is often 
the case, conferred biological benefits are also accompanied by a number of attendant hazards.  
This review is intended to briefly describe some of the adverse effects that inevitably 
accompany the highly intricate immune system which relies on efficient interaction of a large 
number of separate components.  The immune system on occasion, lacks the capacity to 
effectively down-regulate and terminate immune responses at the cessation of a crisis, and this 
inability is especially pronounced in the case of the  central nervous system.  The especial  
vulnerability of the nervous system to aberrant immune performance forms the core of many 
intractable neurological diseases.  This tendency to prolong activity beyond its useful 
applicability also worsens with aging (Bektas et al., 2018).  The basis for this malfunction is 
involves failure of some of the key criteria for effective immune functioning.  The increasing 
lifespan together with exposure to a growing range of xenobiotic agents  may in part account 
for extended age-related inflammatory events.  These are a few means of minimizing their 
adverse effects that include pharmacological strategies together with relatively simple dietary 
and modifications of lifestyle.
2.  General Attributes of Immune Mechanisms
2.1. Decisive features of immune responses 
2.1.1 Intensity
Effective immune functioning depends on a good degree of discrimination by immune 
competent cells.  This must allow for precise targeting of aberrant endogenous molecules and 
species associated with harmful organisms of exogenous origin.  Sometimes, with time, there is 
an increasing strength of the immune response and this can become harmful, leading to allergic 
reactions.  Conversely, certain environmentally prevalent toxic agents are known to  weaken 
the immune system (Kravchenko et al., 2015).  When the strength of the immune response  has 
been compromised, adverse outcomes can include lack of a positive response to infectious 
agents.  In addition, failure of immune surveillance to recognize and remove abnormal cells can 
allow their survival and multiplication, leading to  an elevated risk of cancer.
2.1.2. Specificity
For a useful immune response, the molecular species addressed must remain well 
focused without any significant drifting of identification of the target of the attack.  However, 
another deleterious tendency of deteriorating immune function is a decline in the precision of 
the goal of the response.  
Haptens are low molecular weight materials that are not immunogenic but can bind to 
endogenous proteins which can then become immunogenic.  A characteristic disorder 
associated with such a response is contact dermatitis.  Certain drugs and antibiotics can also act 
as haptens.  An antibody may ultimately be produced that is cross reactive with the unmodified 
parent protein, and this can lead to an auto-immune attack drug-induced form of 
lupus erythematosus.  Systemic lupus erythematosus is a severe disease in which the immune 
system is both inaccurate and hyperactive, attacking and damaging a range of organs.  The 
central nervous system (CNS) can also be involved with neuroinflammatory changes (Duarte-
Delagardo et al., 2019).   Other autoimmune diseases may target on a single tissue in a more 
limited and specific manner (Fig. 1). These include Type 1 diabetes ( involving beta cells within 
the pancreas), Rheumatoid arthritis (cartilage damaged), multiple sclerosis (myelin sheath of 
neurons attacked), myasthenia gravis (acetylcholine receptors at the neuromuscular junction 
ablated), most cases of Addison’s disease (outer layers of adrenal cortex involved), Grave’s 
disease (thyroid gland), pernicious anemia (intrinsic factor producing cells of the stomach), 
inflammatory bowel disease (cells of the digestive tract).  The causal basis of these autoimmune 
disorders is generally unknown.  A major increase in the strength of immune responses is often 
associated with a weakening of the degree of specificity.
2.1.3. Persistence
Restricting the period of activity of  immune responses is important  for their 
constructive and efficient functioning.  Most crises where immune reactions are advantageous 
and fully beneficial to an organism, are transient in nature.  The inflammatory reaction to 
infection involves activation of transcription factors such as NF-kB leading to production of 
inflammatory cytokines and recruitment of macrophages. This facilitates destruction of 
invading organisms and removal of dead cells. When infectious entities or damaged cells are 
successfully disposed of, the healthy immune system then returns to low level surveillance.  
Regrettably however, this is not always the case.  After provocation by a stimulus, immune 
activity often has difficulty is subsiding to levels existing before the appearance of a triggering 
factor.  Those same processes that are valuable in engaging and blocking pathogens and cell 
variants, if excessively extended, can cause serious harm if continued  in a protracted manner.  
Such persistence and failure to terminate responses may underlie several of the chronic 
immune disorders mentioned above.
 An explanation for some situations involving a chronic inflammatory state, is the 
presence of inorganic materials that cannot be resolved by the immune system.  This is the 
situation in lung disease such as silicosis or asbestosis.  Here the inflammation that is caused 
initially by crystalline mineral particles. Since they are similar in size to bacteria, leukocytes will 
respond to inflammation and will attempt to ingest these particles, and this leads to their death 
which signals other leukocytes to aid in countering what is perceived as an infection. Fibroblasts 
are also recruited leading to fibrosis.  Since the mineral particles cannot be cleared by these 
cells, they invoke chronic inflammatory events and an irresolvable site of irritation, eventually 
leading to infiltration of tissues with fibrotic material.  In the absence of any arrest of these 
processes, a persistently developing disease state emerges and continues long after the original 
exposure to the mineral particles (Leung et al., 2012).  It may be that a parallel inability to 
effectively clear amyloid plaques within the CNS accounts for the excess inflammation 
associated with Alzheimer’s disease (Clayton et al., 2017).
2.2.   Inappropriate continued activity of the immune system
The intricacy and subtlety of the mammalian immune system has resulting in the 
emergence of many undesirable and harmful side effects.  Current hygienic and medical 
practices together with an increasingly urban life style, have resulted in a diminished challenge 
of exogenous pathogenic organisms.  However, this has coincided with the emergence of a 
range of novel allergens and hapten-forming materials.  The prevalence of several common 
auto-immune diseases including multiple sclerosis, systemic lupus erythematosus (SLE), and 
type 1 diabetes mellitus has been rising (Parks et al., 2014).  Many types of cancer are also likely 
to involve chronic inflammation (Hunter, 2012).  Since the development of persistent 
inflammation, often of idiopathic origin is increasing, it is crucial to endeavor to identify those 
factors that may underlie this. Two of these features are related to the onset of increasing 
insensitivity to key regulatory hormones, insulin and glucocorticoids such as cortisol.
2.2.1. Insulin
The development of resistance to insulin is characteristic of Type II diabetes, and  
metabolic syndrome (Saltiel and Olefsky 2017). Failure of tissues to respond to insulin results in 
their not removing glucose from the circulation leading the hyperglycemia.  This is often causal 
to metabolic syndrome, involving, obesity, hypertension, and high levels of circulating 
cholesterol (Balakumar et al., 2016). These defects can be promoted by M1-polarized pro-
inflammatory macrophages (Castoldi et al., 2016).  Although obesity can lead to diabetes, the 
relation between insulin resistance and obesity seems to be interactive rather than one factor 
being clearly causal to the other with each being able to potentiate the other.  Both disorders 
and also metabolic syndrome are characterized by low grade but persistent inflammation 
(Frydrych et el., 2018).  Type II diabetes has global effects and is associated with increased risk 
of cognitive impairment and of Alzheimer’s disease (de la Monte et al., 2015).  This likely due to 
impaired responsivity of the brain to insulin and mitochondrial dysfunction (De Felice and 
Ferreira, 2014, Sripetchwandee et al., 2018).   Normal aging has been correlated with 
increasing unresponsiveness to insulin, and the conservation of responsivity to insulin 
sensitivity is associated with familial longevity (Kullmann et al., 2016).
2.2.2 Glucocorticoids
The inflammatory response is frequently terminated by the action of glucocorticoid 
hormones (Cohen et al., 2012).  However, prolonged activation of glucocorticoid receptors can 
lead to their decreased sensitivity to steroids. This insensitivity can reduce the normal capacity 
of glucocorticoids to inhibit inflammatory activity (Bekhbat et al., 2017).  Such suppression of 
glucocorticoid regulation can also be promoted by extended psychological stress  (Stark et al., 
2001).  It has been suggested that persistently excessive levels of glucocorticoids lead to 
glucocorticoid resistance, and may form the basis of  neuroinflammatory  priming in the aging 
brain (Fonken et al., 2018).
2.2.3 Aging and the senescence-associated secretory profile
Aging is commonly characterized by the presence of chronic, low-grade inflammation 
even in the absence of apparent infection (Franceschi and Campisi, 2014).  This is combined 
with increasing incidence of widespread pathological states including obesity, diabetes, and 
heart disease.  The root of this may relate to the characteristic senescence-associated secretory 
profile (SASP) of aged cells with an arrested cell cycle. This profile incorporates discharge of a 
range of pleiotropic inflammatory cytokines such as interleukin-6 (IL-6) (Kennedy et al., 2014). 
This SASP profile, can cause aging to be connected with high levels of inflammation that are 
unrelated to an exogenous stimulus of immune activation.   Rather than being protective, the 
SASP spectrum promotes angiogenesis, cell proliferation, cancer invasiveness, atherosclerosis 
and neurodegeneration (Rea et al., 2018), a reversal of healthy immune function.
2.2.4 Environmental factors
It has been proposed that increased incidence of inflammation-related disease is largely 
due to the increased range of novel man-made chemicals that are present in the environment 
and in foods (Schmidt, 2011, Lerner and Matthias, 2015).  Such xenobiotic factors of 
anthropogenic origin may  relate to age-related elevated basal levels of inflammation.  Metal-
containing airborne particulate matter can effect upregulation of inflammation related genes 
within the CNS (Ljubimova et al., 2018) and such air pollution is very prevalent in many urban 
centers.  A wide range of lifestyle and dietary choices together with other aspects of modern 
urban life may also contribute to  chronic, systemic inflammatory processes (Egger and Dixon, 
2014).  An association has been made between the extent of exposure to several 
environmental contaminants and the prevalence of Alzheimer’s disease (Yegambaram et al., 
2015).
Normal aging involves remodeling of the chromatin and distinctive epigenetic changes 
in the patterns of DNA methylation and in the non-coding miRNA profile.  Dysfunctional 
epigenetic events play a causal role in various neurodegenerative processes  (Lardenoije et al., 
2015).
Overall, the immune system has many problematic aspects and as these negative 
features become more pronounced with age, they may gradually prevail over the beneficial 
properties of the immune system. While misguided immune activity may target specific organ 
systems, liberation of circulating factors such as inflammatory cytokines can lead to more broad 
organ involvement.  This can jeopardize the integrity of remote tissues (Bernardi et al., 2015), 
including the nervous system (Solas et al., 2017).
In summary, the critical features of immune responses described above, all tend to flow 
toward a less beneficial balance point with age.  Specificity is reduced, persistence is excessively 
prolonged and  while the intensity of the response to authentic immune challenges is more 
inappropriate, despite elevated levels of inflammation.
3.  The Immune System and the Brain
3.1.  Susceptibility of the nervous system to prolonged systemic immune activity
Immune cells regulate many aspects of the nervous system.  This occurs from the very 
start of ontogeny, and  includes the pruning and elimination of neurons and their synapses 
during development as well as the subsequent organization of neuronal plasticity throughout 
the lifespan.  Interactions between immune cells and the nervous system are  bidirectional and 
coordinated so as to optimize somatic responses  to infectious pathogens (Dantzer, 2018). 
The adult central nervous system is partially protected by the blood-brain barrier. The 
endothelial cells of cerebral capillaries are coupled by tight junctions, leading to restricted the 
transfer of many high molecular weight materials.  The idea that the brain thus has an 
“immunologically privileged” insulation from the systemic immune system has been extensively 
revised and diminished in recent years, especially since the discovery of the meningeal 
lymphatic (glymphatic) system (De Mequita et al., 2018).  While the access of immune cells to 
the brain is limited, some immunocompetent cells are able to traverse the blood brain barrier 
and take up residence in the brain. Microglia are the innate immune cells, resembling 
macrophages, that are normally present in the brain. However, single-cell RNA sequencing has 
provided results suggesting that some of these are derived from systemic monocytes (Goldman 
et al., 2016, Ginhoux and Garel, 2018). While infiltrating monocytes come to closely resemble 
intrinsically resident microglia, they may be functionally different and more liable to promote 
autoimmune attack on nervous tissue (Li and Barres, 2018).  Thus, peripherally derived 
macrophages infiltrating into the brain underlie the onset and continuation of repeated social 
defeat-induced anxiety like behavior in mice (Wohleb et al., 2014).  On the other hand, native 
resident microglia often act in a more supportive manner such as promotion of remyelination in 
multiple sclerosis (Lloyd et al., 2017).  Although the proportion of cerebral microglia that are of 
systemic origin, derived from monocytes, is elevated in some neurodegenerative diseases,  it 
has been proposed that such infiltrating cells may have distinctive beneficial  qualities(London 
et al., 2013).  
Other means by which a general inflammatory process may infiltrate the brain from the 
periphery include afferent signaling through the vagus nerve, and  by way of disease-effected 
weakening of the brain’s barrier systems (Kempuraj et al., 2017).  Necrosis induced by 
radiotherapy of brain tissue can also lead to infiltration of inflammatory macrophages (Furuse 
et al., 2015).  Several studies have reported that  induction of systemic inflammation can 
produce many changes reminiscent of neurodegenerative disease in the brain which may 
involve a  secondary excessive microglial response (Cunningham, 2013).   By this means chronic 
inflammatory diseases relating to a single organ system, have the potential to augment the 
onset and progression development of several age-related neurological diseases.  Persistent 
systemic inflammatory conditions, such as atherosclerosis, diabetes, cancer, sepsis and obesity 
have been associated with increased risk of a variety of neurological disorders including stroke 
(Drake et al., 2016), Alzheimer’s disease (Holmes 2013), and Parkinsonism (Qin et al., 2007), as 
well as schizophrenia (Beumer et al., 2012), depression (Dowlati et al., 2010), and autism (Li et 
al., 2009).   All of these CNS disorders have been reported as being accompanied by 
neuroinflammation, and consequently, the use of anti-neuroinflammatory therapies has often 
been advocated as an adjunct in the treatment of systemic disorders (Kern et al.2016, Kohler et 
al., 2016, Meneses et al., 2019).  In the case of stroke, the ischemia that initially follows can 
lead to a peripheral inflammatory response, followed by compensatory immunosuppression.  
This latter event can then increase susceptibility to infection and result in elevated mortality.  
Some of the interactions that link the immune responses of the brain to those taking place 
within the entire organism are illustrated in Figure 1.
Overall, measures of brain aging and dementia risk factors are related to the extent of 
systemic inflammation and this rises with age (Corlier et al., 2018).  A striking example of the 
general immune system and that of the brain, is the consequence of a single systemic injection 
of lipopolysaccharide (LPS).  This caused levels of the inflammatory cytokine TNF- to be 
elevated in many organs.  However, while these values returned to normal within a week in 
most tissues, TNF remained elevated in brain for over 10 months. This was associated with 
microglial activation and neurodegenerative changes in the brain (Qin et al., 2007).  This report 
well illustrates the incapacity of the brain to rapidly restore homeostasis after an inflammatory 
shock.  Systemic inflammation can worsen behavioral shortcomings in both aged animals (Chen 
et al., 2008) and in humans with neurodegenerative disease (Murray et al., 2012).  The 
prolonged maintenance of adverse experience by the nervous system could underlie this. 
Reactivation of quiescent lesions by  LPS in the EAE model of multiple sclerosis reveals that 
distant inflammatory events can enable renewed progression of indolent brain lesions (Moreno 
et al., 2011). 
Another means by which disease states in non-nervous tissues can transmit pathological 
events to the brain despite the limited access granted by the blood brain barrier, may involve 
subcellular cytoplasmic vesicles called exosomes. Exosomes are extracellular vesicles that are 
released from cells upon fusion with the plasma membrane. This liberates vesicles into the 
extracellular fluid from whence they can travel widely. They contain a large range of 
macromolecules.  miRNAs are an important part of their cargo.  By transport of their contents 
into other cells, exosomes may enable the dissemination and progression of several 
diseases. Migration into the brain, of exosomes in serum derived from LPS-treated mice, results 
in inflammatory responses and gliosis (Li et al., 2018).  Such vesicles can carry immune-
activating information across the blood brain barrier, in the absence of inflammatory molecules 
(Villaseñor et al., 2019).  
Table 1 summarizes some of the disorders, both of systemic and of nervous origin, that 
can be associated with elevated levels of inflammation in the nervous system.  The causal 
sequence of these correlations is not always obvious.  It should be borne in mind that 
neuroinflammation is not only a result of some wide-ranging diseases encompassing the whole 
organism, but it is bi-directional in that it can also be the cause of such diseases.  An example of 
this is the evidence that inflammation within the CNS can lead to hypertension (Haspula and 
Clark, 2018).
3.2.  Role of macrophages,  microglia and astroglia
3.2.1.  Polarity of activated immune cells
Macrophage and microglial activation has been loosely classified as proceeding in one of 
two opposite directions. The M1 phenotype is a pro-inflammatory state, in which macrophages 
and microglial cells produce and release reactive oxygen species and inflammatory cytokines 
such as  tumor necrosis factor-α (TNF-α)and interleukin 6 (Il-6). The M2 state, is not 
inflammatory and is engaged in the production of anabolic factors, including brain derived 
neurotrophic factor (BDNF) (Tang and Le, 2016).  In the normal CNS microglia may be polarized 
toward a more M2 phenotype, but with inflammation, these cells  express M1 markers.  
Neither of these expression states is intrinsically harmful, but unbalanced overemphasis of M1 
together with diminution of M2 markers may initiate destructive events.    For example, 
promoting a more M2 configuration of microglia can improve functional recovery following 
traumatic brain injury (Loane et al., 2014) while induction of M1 polarization with 
lipopolysaccharide results in repression of telomerase-associated genes implying cell 
senescence (Kronenberg et al., 2017).  Both M1 and M2 configurations of macrophages and 
probably microglia possess phagocytic activity, and this can be associated with targeted cell or 
micro-organism removal, or with overall tissue repair and remodeling events (Boche et al., 
2013).   Each of these states represents a transition from a relatively dormant cell, but the 
outcomes of each type of activation are very different.
At the onset of AD, microglia are predominantly activated as the M2 form while as the 
disease progresses, the activation is more directed toward the inflammatory M1 form (Shen et 
al., 2018).  This type of transition is also found following ischemic stroke (Wang et al., 2018).  
The immune response to acute cerebral ischemia is a major factor in determining the outcome 
following acute ischemic stroke (Anrather and Iadecola, 2016). However, in glial tumors where 
inflammation is low and anabolic processes predominate,  the presence of markers of the M2 
phenotype predominates over markers for M1, and this facilitates tumor progression (Sasaki, 
2017).  Since a broad spectrum of intermediate states between M1 and M2 phenotypes exists, 
a simple separation into these two classes is insufficient.  Nevertheless, this division albeit 
imprecise can be useful in outlining the characteristics generally associated with each cell type 
(Table 2). 
Neuroinflammation is likely an important factor in accounting for age-related cognitive 
decline (Bettio et al., 2016).  In a clinical study, macrophages derived from patients with mild 
cognitive impairment (MCI), were unable to phagocytize and degrade amyloid-β1 - 42 (Aβ).  
Dietary administration of ω-3 fatty acids, antioxidants, vitamin D3, and resveratrol together, 
restored the ability of macrophages to  clear amyloid and phagocytose unfolded proteins and 
slowed down the rate of cognitive decline.  This was accompanied by a phagocytic macrophage 
type, whose expression profile reflected a combination M1 and M2 characteristics (Fiala et al., 
2018).  Microglia cannot simply be described as either dormant or activated as they are very 
responsive to the surrounding milieu which can rapidly alter the spectrum their gene 
expression profile in a complex rather than a binary manner (Gosselin et al., 2017).
Generally, there is clear evidence that the switch of microglia from the M1 to M2 
phenotype is able to  lessen adverse changes in animal models of AD, by attenuation of 
inflammation (Yao and Zu, 2019), and this has been associated with improved cognition (Zhu et 
al., 2016). Alternatively activated microglia in the M2 form are largely involved with tissue 
repair, phagocytosis of misfolded proteins and dead cells, while the classical M1 configuration 
predominates in neurodegenerative  states (Manchikalapudi et al., 2019) and can promote 
protein misfolding (Tang and Le, 2016).  A range of pharmacological strategies have been 
suggested in order to effect the transition toward the M2 state (Yao and Zu, 2019).  While 
treatments for neurodegenerative disease may attempt a polarization toward the M2 form of 
microglia, therapy for glioma is likely most beneficial when directed toward inducing a M1 form 
(Song and Suk, 2017).  Rebalancing the equilibrium of microglial polarity toward either anabolic 
or inflammatory events can have significant therapeutic relevance (Kanazawa et al., 2017).  
3.2.2.  Microglial ablation studies
The ability to selectively ablate microglia by pharmacological means has led to much 
recent work on this strategy involving their transient depletion.  While this is a very active area, 
consensus has not yet been reached on whether the role of microglia is largely beneficial or 
detrimental.  
In the study of neurodegenerative or brain trauma, reports concerning the 
advantageous nature of glial ablation predominate. Thus animal models of Alzheimer’s disease 
(AD) respond well to elimination of microglia, exhibiting diminished formation of amyloid 
plaques (Spangenberg et al., 2019).  As a result, pharmacological removal of microglia, followed 
by repopulation has been suggested as a potential therapy for a variety of neurodegenerative 
disorders (Han et al., 2019).  Microglial removal has also been described as beneficial in a 
variety of conditions including reduced severity of postoperative inflammation (Feng et al., 
2017), and a diminished response to acute ethanol withdrawal (Walter and Crews, 2017).  
However, there are also reports that conflict with the concept that microglial removal 
confers benefits. In another mouse model of AD, ablation of resident microglia allowed 
penetrance of peripheral macrophages in to the brain and the emergence of increased 
expression of inflammatory genes and  a much more pro-inflammatory milieu (Unger et al., 
2018).  The ablation procedure also blocked host defenses against prion disease (Carroll et al., 
2018) and against picornavirus infection of the brain (Sanchez et al., 2019).  Evidence for the 
useful role of microglia includes a report that their depletion exacerbates post-ischemic 
inflammatory damage within the brain (Jin et al., 2017).  Finally, effecting repopulation of 
microglia subsequent to their depletion in aged mice reverses cognitive and morphological 
defects (Elmore et al., 2018).  
The subtle nature of microglial functioning has yet to be clarified.  While it is obvious 
that microglia play an essential supportive role in nervous tissue, they appear under some 
common circumstances, to undergo pathological  transformation to a form where they enhance 
and promote disease processes.   Perhaps the best clue to resolving these apparently 
contradictory findings, comes from the report of Garcia-Agudo et al., (2019). This group found 
that while microglia depletion transiently benefitted  genetically induced brain inflammation, a 
residual surviving microglial species  which was aggressively inflammatory and destructive, soon 
expanded.  This led to no long term improvement whatsoever in  treated mice.  Detailed 
investigation of the variety of microglial species and the kinetics of their proliferation in 
response to an altered environment, are a complex challenge but may explain the reason 
underlying the many inconsistent reports on this topic.
3.2.3.  Astroglia
Brain inflammation is also enabled by astroglia which respond to adverse events in the 
CNS by undergoing reactive gliosis, and displaying inflammatory markers such as glial fibrillary 
reactive protein (GFAP)(Norden et al., 2015).  There is extensive supportive interaction between 
microglial and astroglial activity, and with age (Crotti and Ransohof, 2016), this leads to 
progressively increasing basal levels of cerebral basal inflammation (Primiani et al., 2014).  This 
increase is especially pronounced in the presence of neurodegenerative disorders (Kabba et al., 
2018).
Astrocytes resemble microglia in that they have both a positive and an undesirable role 
in maintaining cerebral function.  They can clear dead cells (Lui et al., 2018), and form a border 
between neural cells and other tissues such as blood vessels and the meninges.  However they  
are able to act as viral reservoirs, and may thus prolong viral in the brain (Li et al., 2016). In 
addition, astrocytes are  capable of apparently unprovoked reactive gliosis that involves 
enhanced production of inflammatory cytokines, and reactive oxygen species, changes that can 
interfere with neuronal structure and function.  In addition to AD, several other 
neurodegenerative disorders are associated with astroglial activation, including Parkinson’s 
disease (PD) and multiple sclerosis (MS) (Stephenson et al., 2018).  Astroglia are also capable of  
expressing anti-inflammatory properties, and this duality may account for the waxing and 
waning nature of MS (Sofroniew, 2015).  Inhibition of reactive astrogliosis  has been reported to 
intensify beta-amyloid peptide  deposition and to increase levels of inflammation in a mouse 
model of AD  (Kraft et al., 2013).  Conflicting findings related to the role of astroglia in 
neurodegenerative disease may also reflect their  capacity to exist in several activated states 
with strikingly different properties (Liddelow and Barres 2017).  Induction of 
neuroinflammation with lipopolysaccharide leads to formation of a detrimental type of reactive 
astrocyte, while the reactive astrocytes generated after ischemia, have a gene expression 
profile reflecting more protective qualities (Zamanian et al., 2012).  These have been termed A1 
and A2  respectively, paralleling the M1/M2 distinction of microglia (Lidelow and Barres, 2017).  
On the whole, reactive astrocytes seem predominantly deleterious in AD and their suppression 
offers a promising therapeutic strategy (Ceyzériat et al., 2018).
3.2.4.  Micro-RNAs
In recent years, micro-RNAs  (miRNAs) have emerged as major cytoplasmic regulators of 
post-transcriptional activity of their corresponding messenger RNAs.  A single miRNA may act 
on many different mRNA targets (Friedman et al., 2009) and this breadth makes these 
molecular species particularly powerful in control of biological function.   miRNAs play an 
important role in influencing macrophage/microglial activity and thus  as critical modulators of 
immunity and inflammation.   miR-124 facilitates downregulation of indices of the M1 
phenotype such as  the inflammatory cytokines IL-6 and TNFα while M2-linked markers such as 
neurotrophic and growth factors are upregulated (Ponomarev et al., 2013). miR-124 is the most 
highly expressed miRNA in neurons and is also  present in large amounts in immune cells (Qin et 
al., 2016).   Additionally, miR-124 appears to be essential for the initiation and maintenance of 
the M2 phenotype (Qin et al., 2016) and is also important in maintenance of cerebral 
vasculature and inhibition of neuronal apoptosis (Che et al., 2019, Li et al., 2019).  In contrast, 
miR-155 is oriented toward promotion of the microglial polarization toward a more 
inflammatory  posture (Guo et al, 2019).  Transcriptome analysis of microglia from models of 
neurodegenerative diseases often exhibit heighted levels of both M1 and M2 markers together 
(Sarlus and Heneka, 2017).  
Whether or not the activity of a specific miRNA is supportive or harmful is very 
dependent on the target issue.  For example miRNA-21 administration can mitigate the 
magnitude of brain injury by inhibition of inflammation and apoptosis.  Thus it has been 
suggested as a possible treatment for stroke (Ge et al., 2016).   On the other hand, this same 
miRNA is implicated in  the promotion of neoplastic transformation, angiogenesis support and 
growth of glioma (Chai et al., 2018). 
3.3. Potential therapeutic directions 
A wide range of pharmacological and phytochemical tactics are being investigated to 
both to understand the basis of,  and to devise means of mitigating the age related progression 
of inflammatory disorders.  Three possible strategies are listed:
3.3.1  Mitochondrial protection
Chronic inflammation leads to impaired functioning of the mitochondrial tricarboxylic 
acid cycle which leads production of excess free radicals. This can be mitigated by 
dimethylfumarate which exerts an anti-inflammatory effect by both inhibiting mitochondrial 
aerobic glycolysis (Kornberg et al., 2018), and activation of the nuclear factor erythroid 2–
related factor 2 (Nrf-2) signaling pathway (Giustina et al., 2017).  Dimethylfumarate 
administration has been found useful as a means of reducing immune responsivity, and has 
clinical utility in the treatment of multiple sclerosis (Wingerchuk and Weinshenker, 2018).
3.3.2 Slowing onset genetic changes characterizing aging
Another tactic could be to develop means to retard the changes in gene expression and 
miRNA profile taking place with aging.   These changes are tilted toward increased 
manifestation of inflammatory gene activity (Victoria et al., 2017, Sharman et al., 2004).  These 
changes could be remedially addressed by use of inexpensive agents such as melatonin, which 
has been shown to reverse many of the age-related changes modification of the gene 
expression profile, especially those relating to immune activity (Bondy, 2018).  Melatonin 
declines rapidly with age (Lahiri et al., 2001a) but cortical levels can be elevated by dietary 
administration. Such treatment can also reduce levels of amyloid peptides in an 
experimental animal model (Lahiri et al., 2001b).
3.3.3 Reduction of glycemic potency of diet and increase of physical activity
A  marked association between diets with a high inflammatory potential and less 
favorable measures of brain and cognitive health, has been made among the elderly (Gu et al., 
2018).  The rapid evolution of the incidence of immune-mediated inflammatory diseases among 
immigrants, further suggests a role for non-genetic factors and gene-environment interactions 
(Agrawal et al., 2019).  It then follows that appropriate environmental modifications could be 
promptly useful in reducing the prevalence of these disorders.  This is consistent with the 
promotion of a suggested ketogenic diet in order to broadly control systemic inflammation 
(Dupuis et al., 2015, Puchalska and Crawford, 2017).  The utility of regular exercise in 
attenuating age-related inflammation has similarly been frequently attested to (Garatachea et 
al., 2015).  These changes could be effected readily without the necessity for development of 
specific new drugs and would be low cost. It has been advocated that this dietary approach may 
be of especial value in the treatment of neurodegenerative diseases (McDonald and, Cervenka, 
2018).  The development of more sophisticated means to maintain the selectivity and efficiency 
of immune responses with senescence, is a growing medical concern and a challenge for the 
future.  However this dietary approach is limited only by the ability to convince people to make 
relatively simple changes, but that demand a degree of determination to modify their routines.  
3.3.4  A role for immunotherapy
The potential for immunotherapy for moderation of senescence-related or 
neurodegenerative events has been widely studied but overall, success in this area remains 
elusive.  The development of antibodies specific for undesirable peptides, while most promising 
in animal models, has not  proved as useful in clinical trials as hoped, and has sometimes led to 
serious undesirable side effects (Wisniewski and Goñi, 2015, Valera et al., 2016).  However a 
less focal approach involving intravenous administration of general immunoglobulins  (IVIG) has 
been more promising and has minimal toxic sequelae (Vitaliti et al., 2017, Thom et al., 2017).  
Nevertheless, this area is currently being intensively investigated and in dynamic flux, thus 
offering much hope in the future.
4.  Conclusion
The listing of the pathological consequences of excess immune activity, should not 
obscure the fact that the immune system has been maintained and enriched with time by 
evolutionary processes, indicating its great value.  The issue then arises as to why then there 
are so many instances of aberrant and excessive inflammation.  There are several possible 
explanations for this, many of which relate to the prevailing life style.  The way of life today 
often contains less physical activity  and a greater dietary abundance than over the large 
timespan of human existence.  These features can account for the prevalence and likely 
increase of many disorders with an inflammatory component.  But perhaps the most significant 
factor to be considered, is the increased lifespan of modern times.  This prolongation beyond 
reproductive years implies that no further evolutionary pressures can be exerted in later life.  
Thus any aberrant metabolism of the elderly cannot be amended by selective forces.  The 
immune system functions efficiently in the young, but cannot respond as successfully to the 
new demands placed on it by extended survival.  It is noteworthy that the large majority of  
disorders including an undesirable inflammatory component, become increasingly pronounced 
with age.  All three of the distinctive features of immune responses described above, become 
less effective with age.  The efficiency of the immune response may be gradually, compromised 
by the combination of a loss of selectivity together with protracted inflammatory activity.  In 
this manner, the adverse effects of immune activity gradually become more pronounced and 
persistent and slowly displace the many positive features of immune defense. However, there 
are accessible means of moderating this inevitable deterioration that could readily be acted 
upon. It is urgent that relevant information be more generally directed to a more extensive 
audience.
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Fig. 1   Representation of factors by which systemic immune activity may lead to prolonged inflammatory responses in thrcentral nervous system
  Central Nervous System Reaction 
Increased Target Penumbra 
 Systemic Inflammatory 
Response
   Exogenous immune stimuli
Age
Failure of Response Shutdown
Intrinsic  Immune 
Stimuli
M1/M2 polarity Exosomes, Vagal input,Macrophage infiltration
            Table 1. 
Adverse health conditions associated with neuroinflammation.
                         
_______________________________________
______________Disturbances of Nervous Origin_______
Neurodegenerative disease (AD, PD, Stephenson et al., 2018
HD, MS, ALS)
Brain irradiation Furuse et al., 2015
Traumatic brain injury Corrigan et al., 2016
Stroke Anrather and Iadecola, 2016
Depression Kohler et al., 2016
Autism Kern et al., 2016
_____________Disturbances of Systemic Origin________
Aging  Bettio et al., 2017
High fat diet  Spencer t al., 2017
Abnormal gut microbiota  Russo et al., 2018
Inhalation of particulate matter  Ljubimova et al., 2018
Peripheral inflammation  Demers et al., 2018
Diabetes  Muriach et al., 2014
Hypertension  Haspula et al., 2018
Lupus  erythematosus  Makay, 2105
Sepsis Meneses et al., 2019
Table 2.  
Comparison of properties of macrophages/microglia at the two poles of differing states of 
activation.
  _____________________________________________________________________________  
Promoted by M1 type cell polarization 
(classical activation)
Promoted by M2 type cell polarization
(alternative activation)
Bacteriocidal events promoted Anabolic, Reconstructive processes in injured 
tissues
Attempt to phagocytose tumor cells, 
promotion of T-cell responses
Tumor progression, angiogenesis and 
resistance to chemotherapy enhanced
Inflammatory factors produced Anti-inflammatory cytokines produced
M1 polarity elevated rapidly after injury, 
removal of dead cells
Delayed increase of M2 type after injury, repair 
initiated
Diabetes, insulin resistance elevated Insulin sensitivity restored, plasma glucose 
levels regulated
Obesity Adipose tissue homeostasis maintained
Enriched in atherosclerotic plaques Regression of atherosclerosis 
Induced by misfolded proteins Clearance of misfolded proteins, and beta 
amyloid
Promotion of elevated inflammation, 
apoptosis, neurodegenerative disease 
Phagocytosis
Neuroprotection after traumatic brain injury.
Tissue remodeling after stroke
Phagocytosis
Repression of telomere complex genes Upregulation of genes related to bioenergetic 
metabolism
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